- Global Pharma News & Resources

Atrial Fibrilillation Study by NativeCardio and the Texas Heart Institute Show Ultra-Low Cardioversion is Possible

NEW YORK - January 24, 2022 - (

NativeCardio Inc., a cardiac medical device manufacture, announced today it's study the 'Ultra-low energy cardioversion in a pig model of postoperative atrial fibrillation (POAF): A Feasibility Study' has been recognized and published by HeartRhythm. The study, conducted in conjunction with the Texas Heart Institute, evaluated the feasibility and effectiveness of ultra-low energy electrical cardioversion through epicardial leads using NativeCardio's novel external defibrillation interface module (EDIM) 'Rhythm Maker™'.  

"All of us at NativeCardio are very pleased by the results of this study of ultralow cardioversion to convert postoperative atrial fibrillation," the company's President and Co-Founder, Dr. Joseph Pergolizzi said. "Postoperative atrial fibrillation is a common complication following cardiac surgery that can result in morbidity and even mortality. While it occurs more often after heart surgery, recent research has found it may also occur after other types of noncardiac surgery and, in fact, in those settings may be even more dangerous. NativeCardio is working at a device-based solution to help monitor and effectively treat postoperative atrial fibrillation with ultralow amounts of energy for improved patient comfort. This publication confirms the feasibility of our model."

"The results of this study show NativeCardio's EDIM 'Rhythm Maker™' demonstrated that ultra-low energy conversion from atrial fibrillation to normal sinus rhythm is possible," World-Renowned Cardiac Surgeon at Houston Methodist Hospital's DeBakey Heart & Vascular Center in Houston Texas, Dr. Randall Wolf said. "This represents a potential safer, quicker, and possibly painless alternative to the conventional electrical conversion approach, besides eliminating the exposure to the side effects of antiarrhythmic medications. Further research is needed to provide further data into the safety, feasibility, and mean DFTs that can be achieved through this device."

Gary Dixon, Executive Vice President at NativeCardio noted, "the study from the Texas Heart Institute is further validation that our model of using very low amounts of energy delivered directly to the heart to convert postoperative atrial fibrillation can be effective. We are grateful to the investigators in this study and we hope to move forward soon to bringing this important new technology to patients."

About Native Cardio Inc.

NativeCardio, Inc., is a cardiac medical device manufacturer located in Naples, FL.  We have developed the Rhythm Maker™, a technology that addresses a critical unmet need that often manifests following cardiovascular, thoracic, and abdominal surgery. We are referring to postoperative atrial fibrillation (POAF). POAF is highly prevalent, must treat cardiac condition. Our patented technology utilizes a novel approach to deliver ultra-low energy cardioversion directly to the atria of the heart. The system is cost-efficient, reduces expenditures, and offers an effective and precise treatment solution without the severe side effects often associated with current treatment options. 

About Texas Heart Institute

The Texas Heart Institute, founded by world-renowned cardiovascular surgeon Dr. Denton A. Cooley in 1962, is a nonprofit organization dedicated to reducing the devastating toll of cardiovascular disease through innovative and progressive programs in research, education, and improved patient care. THI's scientists and physicians conduct fundamental biomedical, translational, and clinical research in cardiology, cardiovascular surgery, molecular-based medicine, stem cell, and gene therapy, and regenerative medicine both independently and in collaboration with organizations worldwide. As global leaders of patient care for nearly six decades, Texas Heart Institute has been ranked among the top cardiovascular centers in the United States by U.S. News & World Report for the past 30 years. THI is dedicated to spreading awareness and sharing updates on ways to prevent, treat and defeat the cardiovascular disease. With over 10 million visitors coming to its website from around the world every year, is just one of the ways THI is helping to educate people on the importance of heart health.


Media Contact:

Gary Dixon
(813) 404 6348

Press Release Service by

Original Source: Atrial Fibrilillation Study by NativeCardio and the Texas Heart Institute Show Ultra-Low Cardioversion is Possible

Editor Details

  • Company:
    • Newswire
Last Updated: 24-Jan-2022